EVT planning to restart EndoVascular Grafting System trials by year-end.
This article was originally published in The Gray Sheet
ENDOVASCULAR TECHNOLOGIES ENDOVASCULAR GRAFTING SYSTEM CLINICALS are expected to recommence before the end of 1995, company President and CEO Jim Fitzsimmons said at a May 16 session of the Alex. Brown & Sons Health Care Seminar in Baltimore. Earlier this year, the privately held company voluntarily suspended two trials following discovery of breaks in the attachment component of the grafting system ("The Gray Sheet" Feb. 27, p. 13). The suspended studies -- a Phase II trial of the EndoGraft tube vascular graft implant and a Phase I study of the bifurcated EndoGraft -- were evaluating the systems in the treatment of abdominal aortic aneurysms.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.